

- American Cancer Society. Cancer facts & figures 2014. <http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf>. Accessed September 5, 2014.
- Nelson HD, Westhoff C, Piepert J, et al. Screening for ovarian cancer: Brief evidence update. <http://www.uspreventiveservicestaskforce.org/uspstf/uspsovar.htm>. Accessed April 7, 2012.
- Roett MA, Evans P. Ovarian cancer: An overview. *Am Fam Physician* 2009;80:609–616.
- Schorge JO, Modesitt SC, Coleman RL, et al. SGO white paper on ovarian cancer: Etiology, screening and surveillance. *Gynecol Oncol* 2010;119:7–17.
- Kerlikowske K, Brown JS, Grady DG. Should women with familial ovarian cancer undergo prophylactic oophorectomy? *Obstet Gynecol* 1992;80:700–707.
- Pal T, Permeth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. *Cancer* 2005;104:2804–2816.
- Pal T, Mohammad R, Sun P, et al. The frequency of MLH1, MSH2 and MSH6 mutations in a population-based sample of ovarian cancers [abstract]. In: *Proceedings of the 102nd Annual Meeting for the American Association for Cancer Research*; April 2–6, 2011; Orlando, FL. Philadelphia, PA: AACR; 2011. Abstract 5617.
- Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian cancer, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. *Proc Natl Acad Sci U S A* 2011;108:18032–18037.
- Wooster R, Bignel G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. *Nature* 1995;378:789–792.
- Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. *Am J Hum Genet* 1995;57:1457–1462.
- Struwing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. *N Engl J Med* 1997;336:1401–1408.
- Moslehi B, Chu W, Karlan B, et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. *Am J Hum Genet* 2000;66:1259–1272.
- Modan B, Hartge P, Hirsh-Yechezkel G, et al. Parity, oral contraceptives and the risk of ovarian cancer among carriers and non-carriers of a BRCA1 or BRCA2 mutation. *N Engl J Med* 2001;345:235–240.
- American College of Medical Genetics Foundation. ACMG genetic susceptibility to breast and ovarian cancer: Assessment, counseling and testing guidelines. <http://www.health.ny.gov/diseases/cancer/obcancer/pp27-35.htm>. Accessed April 21, 2012.
- American College of Obstetricians and Gynecologists, ACOG Committee on Practice Bulletins—Gynecology, ACOG Committee on Genetics, et al. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. *Obstet Gynecol* 2009;113:957–966.
- American Society of Breast Surgeons. BRCA genetic testing for patients with and without breast cancer. [http://www.breastsurgeons.org/statements/PDF\\_Statements/BRCA\\_Testing.pdf](http://www.breastsurgeons.org/statements/PDF_Statements/BRCA_Testing.pdf). Accessed April 21, 2012.
- Daly MB, Pilarski R, Axilbund JE, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Genetic/Familial High-Risk Assessment: Breast and Ovarian V2.2014. © 2014 National Comprehensive Cancer Network, Inc. [www.nccn.org](http://www.nccn.org). Accessed September 25, 2014.
- Lancaster JM, Powell CB, Kauff ND, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. *Gynecol Oncol* 2007;107:159–162.
- U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Recommendation statement. *Ann Intern Med* 2005;143:355–361.
- Easton DF, Bishop DT, Ford D, et al. Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. *Am J Hum Genet* 1993;52:678–701.
- Ford D, Easton DF, Bishop DT, et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. *Lancet* 1994;343:692–695.
- Easton DF, Ford D, Bishop DT, et al. Breast and ovarian cancer incidence in BRCA1-mutation carriers. *Am J Hum Genet* 1995;56:265–271.
- Narod SA, Ford D, Devilee P, et al. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families: Breast Cancer Linkage Consortium. *Am J Hum Genet* 1995;56:254–264.
- Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. *Am J Hum Genet* 1998;62:676–689.
- The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. *J Natl Cancer Inst* 1999;91:1310–1316.
- Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in a case series unselected for family history: A combined analysis of 22 studies. *Am J Hum Genet* 2003;72:1117–1130.
- Chen S, Iversen ES, Friebel T, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. *J Clin Oncol* 2006;24:863–871.
- Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. *J Clin Oncol* 2007;25:1329–1333.
- Gayther SA, Mangion J, Russell P, et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. *Nat Genet* 1997;15:103–105.
- Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. *Am J Hum Genet* 2001;68:410–419.
- Chenevix-Trench G, Milne RL, Antoniou AC, et al. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: The Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). *Breast Cancer Res* 2007;9:104.
- Rebbeck TR, Mitra N, Domchek SM, et al. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. *Cancer Res* 2009;69:5801–5810.
- Jakubowska A, Rozkrut D, Antoniou A, et al. The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: Results from a multicenter study among 15542 BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res Treat* 2009;121:639–649.
- Ramus SJ, Kartsonaki C, Gayther SA, et al. Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst* 2011;103:105–116.
- Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. *Am J Hum Genet* 2001;68:700–710.
- Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10000 individuals. *J Clin Oncol* 2002;20:1480–1490.
- National Cancer Institute. SEER stat fact sheets: Ovary. <http://seer.cancer.gov/staffacts/html/ovary.html>. Accessed April 8, 2012.
- Stratton JF, Thompson D, Bobrow L, et al. The genetic epidemiology of early-onset epithelial ovarian cancer: A population-based study. *Am J Hum Genet* 1999;65:1725–1732.
- Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. *JAMA* 2000;283:2260–2265.
- Friedlander ML, Dembo AJ. Prognostic factors in ovarian cancer. *Semin Oncol* 1991;18:205–212.
- Evans DGR, Young K, Bulman M, et al. Probability of BRCA1/2 mutation varies with ovarian histology: Results from screening 442 ovarian cancer families. *Clin Genet* 2008;73:338–345.
- Lakhani SR, Manek S, Penault-Llorca F, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. *Clin Cancer Res* 2004;10:2473–2481.
- Mavaddat N, Barrowdale D, Andrulis IL, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the Consortium Investigators of Modifiers of BRCA1/2 (CIMBA). *Cancer Epidemiol Biomarkers Prev* 2012;21:134–147.
- Bolton KL, Chenevix-Trench G, Goh C, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. *JAMA* 2012;307:382–390.
- Ben David Y, Chetrit A, Hirsh-Yechezkel G, et al. Effect of BRCA mutations on the length of survival in epithelial ovarian cancers. *J Clin Oncol* 2002;20:463–466.
- Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. *Cancer* 2003;97:2187–2195.
- Chetrit A, Hirsh-Yechezkel G, Ben-David Y, et al. Effect of BRCA1/2 mutations on long term survival of patients with invasive ovarian cancer: The national Israeli study of ovarian cancer. *J Clin Oncol* 2008;26:20–25.
- Tan DS, Rothermundt C, Thomas K, et al. “BRCAness” syndrome in ovarian cancer: A case-control study describing clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. *J Clin Oncol* 2008;26:5530–5536.
- Roy R, Chun J, Powell SN. BRCA1 and BRCA2: Different roles in a common pathway of genome protection. *Nat Rev Cancer* 2012;12:68–78.
- Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase. *Nature* 2005;434:913–917.
- Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med* 2009;361:123–134.
- Rouleau M, Patel A, Hendzel MJ, et al. PARP inhibition: PARP1 and beyond. *Nat Rev Cancer* 2010;10:293–301.
- Fong PC, Yap TA, Boss DS, et al. Poly(ADP-ribose) polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. *J Clin Oncol* 2010;28:2512–2519.
- Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. *Lancet* 2010;376:245–251.
- Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomized study. *Lancet Oncol* 2011;12:852–861.

56. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. *N Engl J Med* 2012;366:1382–1392.
57. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. *JAMA* 2006;296:185–192.
58. Kauff ND, Domcheck SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: A multicenter, prospective study. *J Clin Oncol* 2008;26:1331–1337.
59. Rebbeck TR, Kauff ND, Domcheck SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst* 2009;101:80–87.
60. Domcheck SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. *JAMA* 2010;304:967–975.
61. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. *J Natl Cancer Inst* 1999;91:1475–1479.
62. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: An international case-control study. *J Clin Oncol* 2005;23:7491–7496.
63. Powell CB, Kenley E, Chen L, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: Role of serial sectioning in the detection of occult malignancy. *J Clin Oncol* 2005;23:127–132.
64. Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomy in 159 BRCA1 and BRCA2 carriers. *Gynecol Oncol* 2006;100:58–64.
65. Domcheck SM, Friebel TM, Garber JE, et al. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. *Breast Cancer Res Treat* 2010;124:195–203.
66. Movahedi-Lankarani S, Baker PM, Giks B, et al. Protocol for the examination of specimens from patients with carcinoma of the ovary. [http://www.cap.org/apps/docs/committees/cancer/cancer\\_protocols/2009/Ovary\\_09protocol.pdf](http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2009/Ovary_09protocol.pdf). Accessed April 14, 2012.
67. Stirling D, Evans DGR, Pichert G, et al. Screening for familial ovarian cancer: Failure of current protocols to detect ovarian cancer at an early stage according to the International Federation of Gynecology and Obstetrics System. *J Clin Oncol* 2005;23:5588–5596.
68. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. *N Engl J Med* 1998;39:424–428.
69. Iodice S, Barile M, Rotmensz N, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: A meta-analysis. *Eur J Cancer* 2010;46:2275–2284.
70. Narod SA, Dube MP, Klijn J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst* 2002;94:1773–1779.
71. Milne RL, Knight JA, John EM, et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. *Cancer Epidemiol Biomarkers Prev* 2005;14:350–356.
72. Haile RW, Thomas DC, McGuire V, et al. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. *Cancer Epidemiol Biomarkers Prev* 2006;15:1863–1870.
73. Lee E, Ma H, McKean-Cowdin R, et al. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: Results from a population based study. *Cancer Epidemiol Biomarkers Prev* 2008;17:3170–3178.
74. Kurian AW, Munoz DF, Rust P, et al. Online tool to guide decisions for BRCA1/2 mutation carriers. *J Clin Oncol* 2012;30:497–506.
75. Watson P, Bützow R, Lynch HT, et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. *Gynecol Oncol* 2001;82:223–228.
76. Weissman SM, Bellcross C, Bittner CC, et al. Genetic counseling considerations in the evaluation of families for Lynch syndrome—a review. *J Genet Counsel* 2011;20:5–19.
77. Palomaki CE, McClain MR, Melillo S, et al. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. *Genet Med* 2009;11:42–65.
78. Weissman SM, Burt R, Church J, et al. Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americans on Inherited Colorectal Cancer Joint Practice Guideline. *J Genet Counsel* 2012;21:484–493.
79. Hendriks YM, Wagner A, Morreau H, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: Impact on counseling and surveillance. *Gastroenterology* 2004;127:17–25.
80. Senter L, Clendenning M, Sotamaa K, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. *Gastroenterology* 2008;135:419–428.
81. Vasen HF, Mecklin JP, Khan PM, et al. The International Collaborative Group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). *Dis Colon Rectum* 1991;34:424–425.
82. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. *Gastroenterology* 1999;116:1453–1456.
83. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. *J Clin Oncol* 2008;26:5783–5788.
84. Barrow E, Alduaij W, Robinson L, et al. Colorectal cancer in HNPCC: Cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. *Clin Genet* 2008;74:233–242.
85. Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. *Int J Cancer* 2008;123:444–449.
86. Pal T, Permut-Wey J, Kumar A, et al. Systematic review and meta-analysis of ovarian cancers: Estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology. *Clin Cancer Res* 2008;14:6847–6854.
87. Crijnen TE, Janssen-Heijnen ML, Gelderblom H, et al. Survival of patients with ovarian cancer due to a mismatch repair defect. *Fam Cancer* 2005;4:301–305.
88. Jensen KC, Mariappan MR, Putcha GV, et al. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. *Am J Surg Pathol* 2008;32:1029–1037.
89. Domanska K, Malander S, Mäsback A, et al. Ovarian cancer at young age: The contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40. *Int J Gynecol Cancer* 2007;17:789–793.
90. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Genetic/Familial High Risk Assessment: Colorectal. V2.2014. © 2014 National Comprehensive Cancer Network, Inc. [www.nccn.org](http://www.nccn.org). Accessed September 25, 2014.
91. Allen BA, Terdiman JP. Hereditary polyposis syndromes and hereditary non-polyposis colorectal cancer. *Best Pract Res Clin Gastroenterol* 2003;17:237–258.
92. Lindor NM, McMaster ML, Lindor CJ, et al. Concise handbook of familial cancer susceptibility syndromes—second edition. *J Natl Cancer Inst Monogr* 2008;38:1–93.
93. Schreiberman IR, Baker M, Amos C, et al. The hamartomatous polyposis syndromes: A clinical and molecular review. *Am J Gastroenterol* 2005;100:476–490.
94. Boardman LA. Heritable colorectal cancer syndromes: Recognition and preventive management. *Gastroenterol Clin North Am* 2002;31:1107–1131.
95. McGarrity TJ, Kulini HE, Zaino RJ. Peutz–Jeghers syndrome. *Am J Gastroenterol* 2000;95:596–604.
96. Beggs AD, Latchford AR, Vasen HF, et al. Peutz–Jeghers syndrome: A systematic review and recommendations for management. *Gut* 2010;59:975–986.
97. Giardello FM, Brensinger JD, Tersmette AC. Very high risk of cancer in familial Peutz–Jeghers syndrome. *Gastroenterology* 2000;119:1447–1453.
98. van Lier MGF, Mathus-Vliegen FMH, Wagner A, et al. High cancer risk in Peutz–Jeghers syndrome: A systematic review and surveillance recommendations. *Am J Gastroenterol* 2010;105:1258–1264.
99. Young RH, Welch WR, Dickersin GR, et al. Ovarian sex cord tumor with annular tubules: Review of 74 cases including 27 with Peutz–Jeghers syndrome and four with adenoma malignum of the cervix. *Cancer* 1982;50:1384–1402.
100. Dozois RR, Kempers RD, Dahlin DC, et al. Ovarian tumors associated with the Peutz–Jeghers syndrome. *Ann Surg* 1970;172:233–238.
101. Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz–Jeghers syndrome. *Nature* 1998;391:184–187.
102. Jenne DE, Reimann H, Nezu J, et al. Peutz–Jeghers syndrome is caused by mutations in a novel serine threonine kinase. *Nat Genet* 1998;18:38–43.
103. Volikos E, Robinson J, Aittomäki K, et al. LKB1 exonic and whole gene deletions are a common cause of Peutz–Jeghers syndrome. *J Med Genet* 2006;43:e18.
104. Salloch H, Reinacher-Schick A, Schulmann K, et al. Truncating mutations in Peutz–Jeghers syndrome are associated with more polyps, surgical interventions and cancers. *Int J Colorectal Dis* 2010;25:97–107.
105. Amos CI, Keitheri-Cheteri MB, Sabirpour M, et al. Genotype–phenotype correlations in Peutz–Jeghers. *J Med Genet* 2004;41:327–333.
106. Meheni H, Resta N, Guanti G, et al. Molecular and clinical characteristics in 46 families affected with Peutz–Jeghers syndrome. *Dig Dis Sci* 2007;52:1924–1933.
107. Aretz S, Steinen D, Uhlhaas S, et al. High proportion of large genomic STK11 deletions in Peutz–Jeghers syndrome. *Human Mutat* 2005;26:513–519.
108. Hearle N, Lucassen A, Wang R, et al. Mapping of a translocation breakpoint in a Peutz–Jeghers hamartoma to the putative PJS locus at 19q13.4 and mutation analysis of candidate genes in poly and STK11-negative PJS cases. *Genes Chromosomes Cancer* 2004;41:163–169.

109. Mehenni H, Gehrig C, Nezu J, et al. Loss of LKB1 kinase activity in Peutz–Jeghers syndrome, and evidence for allelic and locus heterogeneity. *Am J Hum Genet* 1998;63:1641–1650.
110. Boardman LA, Couch FJ, Burgart LJ, et al. Genetic heterogeneity in Peutz–Jeghers syndrome. *Human Mutat* 2000;16:23–30.
111. Vaz F, Hanenberg H, Schuster B, et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. *Nat Genet* 2010;42:406–409.
112. Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. *Nat Genet* 2010;42:410–414.
113. Vuorela P, Pylkäs K, Hartikainen JM, et al. Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility. *Breast Cancer Res Treat* 2011;130:1003–1010.
114. Thompson ER, Boyle SE, Johnson J, et al. Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients. *Hum Mutat* 2012;33:95–99.
115. Osorio A, Endt D, Fernández F. Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families. *Hum Mol Genet* 2012;21(13):2889–2898.
116. Pelttari LM, Heikkinen T, Thompson D, et al. RAD51C is a susceptibility gene for ovarian cancer. *Hum Mol Genet* 2011;20:3278–3288.
117. Loveday C, Turnbull C, Ramsay E, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. *Nat Genet* 2011;43:879–882.
118. Osher DJ, De Leener K, Michils G, et al. Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families. *Br J Cancer* 2012;106:1460–1463.